Yüklüyor......
Enzalutamide in Castration-Resistant Prostate Cancer Patients With Visceral Disease in the Liver and/or Lung: Outcomes From the Randomized Controlled Phase 3 AFFIRM Trial
BACKGROUND: Patients with metastatic castration-resistant prostate cancer (mCRPC) and visceral metastases have a worse prognosis than those with nonvisceral metastases. Treatment with the androgen receptor inhibitor enzalutamide in the phase 3 AFFIRM trial led to significant improvements in outcomes...
Kaydedildi:
| Yayımlandı: | Cancer |
|---|---|
| Asıl Yazarlar: | , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5632943/ https://ncbi.nlm.nih.gov/pubmed/27648814 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30336 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|